P-059: miRNA profiling of CD138+ plasma cells identifies miR-181a-5p overexpression as independent predictor of short-term progression and poor treatment outcome in multiple myeloma

Article2021

miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome

M. Papadimitriou, Αριστέα-Μαρία Παπανώτα, Panagiotis G. Adamopoulos, Katerina‐Marina Pilala, Christine‐Ivy Liacos, Panagiotis Malandrakis, Nefeli Mavrianou‐Koutsoukou, Dimitrios Patseas, Evangelos Eleutherakis‐Papaiakovou, Maria Gavriatopoulou, Efstathios Kastritis, Margaritis Avgeris, Meletios A Dimopoulos, Evangelos Terpos, Andreas Scorilas

Article2025

Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome

Konstantinos Soureas, Panagiotis Malandrakis, M. Papadimitriou, Christos Minopoulos, Ioannis Ntanasis-Stathopoulos, Christine‐Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A Dimopoulos, Andreas Scorilas, Margaritis Avgeris, Evangelos Terpos

Article2023

Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma

Konstantinos Soureas, Christos Minopoulos, M. Papadimitriou, Panagiotis Malandrakis, Panagiotis Adamopoulos, Ioannis Ntanasis‐Stathopoulos, Αριστέα-Μαρία Παπανώτα, Maria Gavriatopoulou, Diamantis C. Sideris, Efstathios Kastritis, Meletios A Dimopoulos, Andreas Scorilas, Evangelos Terpos, Margaritis Avgeris

Article2023

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma

M. Papadimitriou, Konstantinos Soureas, Αριστέα-Μαρία Παπανώτα, Panagiotis Tsiakanikas, Panagiotis G. Adamopoulos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Maria Gavriatopoulou, Diamantis C. Sideris, Efstathios Kastritis, Margaritis Avgeris, Meletios A Dimopoulos, Evangelos Terpos, Andreas Scorilas

Article2023

P-401 MiRNA-seq and clinical validation of miR-221/222 cluster in multiple myeloma

Christos Minopoulos, Konstantinos Soureas, M. Papadimitriou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Adamopoulos, Αριστέα-Μαρία Παπανώτα, Panagiotis Malandrakis, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A Dimopoulos, Evangelos Terpos, Margaritis Avgeris, Andreas Scorilas

Discussion(0)

Related publications

miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome

Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome

Loss of Mir-221/222 Cluster Expression Results in Short-Term Disease Progression and Poor Post-Treatment Outcome in Multiple Myeloma

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma

P-401 MiRNA-seq and clinical validation of miR-221/222 cluster in multiple myeloma